Phaseline

Companies › AskBio

AskBio: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 2; Neurology, Cardiovascular, Metabolic and endocrine; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAV2-GDNF
Adeno-associated virus serotype 2 delivering glial cell line-derived neurotrophic factor (
GDNFPhase 2Parkinson DiseaseAug 2028
AB-1002
Protein phosphatase 1 catalytic subunit beta (PP1β) inhibitor delivered via intracoronary
PPP1CBPhase 2Congestive Heart FailureDec 2030
AB-1009
GAA gene therapy delivered via recombinant adeno-associated virus (AAV)
GAAPhase 1Pompe Disease (Late-onset)Sep 2028
AB-1003
Gene therapy delivering functional FKRP gene
FKRPPhase 1Limb Girdle Muscular DystrophyDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06285643AAV2-GDNFPhase 2Parkinson DiseaseNeurologyAug 2028
NCT07282847AB-1009Phase 1Pompe Disease (Late-onset)Metabolic and endocrineSep 2028
NCT05230459AB-1003Phase 1Limb Girdle Muscular DystrophyNeurologyDec 2028
NCT05598333AB-1002Phase 2Congestive Heart FailureCardiovascularDec 2030

Targets

FKRP (1) GDNF (1) PPP1CB (1) GAA (1)

Companies with the same targets

ML Bio Solutions Atamyo Therapeutics Brain Neurotherapy Bio Astellas GeneCradle Amicus Therapeutics Sanofi Spark Therapeutics

Companies built like this

Elpida Therapeutics SPC MED Institute Neurogene Nippon Shinyaku REGENXBIO

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.